HD-027

Huntington's Disease (HD)

Shanghai 35 years old male China Total Cost: 274

Patient Condition

Early Huntington's disease, CAG repetition number 43, mild chore-like movement, low normal range of cognitive function, MoCA score 25 points. UHDRS TMS 15 points, TFC 13 points. Selected into the clinical trial of intrathecal injection of mesenchymal stem cells (MSC).

Treatment Timeline

PhaseDetailsDate
Clinical trial screening and baseline assessment
MSC stem cell intrathecal injection course 1
MSC Stem Cell Course 2 + Rehabilitation
Follow-up assessment and maintenance rehabilitation

Treatment Outcome

beforeUHDRS TMS 15, TFC 13, MoCA 25, mild choreo-like exercise, normal and low cognitive function
afterUHDRS TMS dropped to 8 points (improved by 7 points), TFC maintained at 13 points, MoCA improved to 27 points, choreo-like movements were significantly reduced, and cognitive function improved
highlightIntrathecal injection of MSC stem cells is safe, motor symptoms are significantly improved, and brain MRI shows a slowdown in striatum atrophy.